7607 Stock Overview
DuoGenic StemCells corporation provides cell therapy products and stem cell culture related services.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
DuoGenic StemCells corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$31.55 |
| 52 Week High | NT$65.10 |
| 52 Week Low | NT$30.95 |
| Beta | 0 |
| 1 Month Change | -5.11% |
| 3 Month Change | -16.86% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -49.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7607 | TW Life Sciences | TW Market | |
|---|---|---|---|
| 7D | -4.7% | -0.2% | -2.3% |
| 1Y | n/a | -24.0% | 27.2% |
Return vs Industry: Insufficient data to determine how 7607 performed against the TW Life Sciences industry.
Return vs Market: Insufficient data to determine how 7607 performed against the TW Market.
Price Volatility
| 7607 volatility | |
|---|---|
| 7607 Average Weekly Movement | 6.3% |
| Life Sciences Industry Average Movement | 5.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 7607 has not had significant price volatility in the past 3 months.
Volatility Over Time: 7607's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | n/a | www.dgsc.com.tw |
DuoGenic StemCells corporation provides cell therapy products and stem cell culture related services. It also offers cell culture medium, synthesize protein, and stem cell scale up solution; and peripheral blood cell purification cell therapy for Osteoarthritis. The company was founded in 2018 and is based in Taichung City, Taiwan.
DuoGenic StemCells corporation Fundamentals Summary
| 7607 fundamental statistics | |
|---|---|
| Market cap | NT$963.95m |
| Earnings (TTM) | NT$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 7607 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7607 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$0 |
| Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 7607 perform over the long term?
See historical performance and comparison